Test a fatty-acid drug for docetaxel-resistant prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests whether blocking fatty-acid production can slow castration-refractory prostate cancer that has already progressed after docetaxel. It may help by targeting cancer growth when standard hormone-level treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have castration-refractory prostate cancer that has progressed after prior docetaxel treatment.
- Your cancer is showing progression based on PSA or new/worsening spots on scans (bones and/or lymph nodes).
- You are age 18 or older.
- Your daily functioning is fairly good (ECOG score 0, 1, or 2).
- You have enough blood counts and organ function (neutrophils, platelets, liver tests, and kidney tests meet limits).
- You can understand the study and sign the consent; also, life expectancy is more than 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests QLC5508, a new targeted drug for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The drug is designed to work in patients whose cancer has progressed despite prior hormone-based treatments.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.